Long-term Benefits of CPAP or MAD Treatment on the Sleep of OSAS Patients

Launched by RESMED · Jun 23, 2022

Keywords

ClinConnect Summary

The REMAP study is looking at how two different treatments, Continuous Positive Airway Pressure (CPAP) and Mandibular Advancement Devices (MAD), help people with Obstructive Sleep Apnea Syndrome (OSAS) sleep better over a year. The study will involve about 400 patients across ten sleep centers in France. Researchers will use special sleep tests done at home to measure changes in sleep patterns and gather information on how patients feel about their sleep and overall quality of life. The goal is to find out which treatment works better and what factors might help improve sleep for those with OSAS.

To participate in the study, individuals need to be between 18 and 80 years old and already diagnosed with OSAS. They should also have previously completed a sleep test. However, people who have been treated for OSAS in the last five years or have certain health conditions, like severe heart disease or respiratory diseases, won't be eligible. Participants can expect to share their experiences and have their sleep monitored over the course of the year, helping researchers understand the long-term benefits of these treatments for better sleep and quality of life.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient already included in the SunSAS study (No. ID/RCB: 2021-A01827-34) or Patient who has undergone polygraphy or polysomnography eligible for treatment with CPAP or MAD in the context of OSA.
• • Patient with a sleep test performed with the Sunrise device
• • Men or Women from 18 to 80 years old
• • Patient with OSAS eligible for CPAP or MAD therapy
• • Affiliated patient or beneficiary of a social security scheme
• • Signed informed consent
• Exclusion Criteria:
• • Patient previously treated for OSAS by CPAP or MAD during the last five years
• • Patient with COPD or other respiratory diseases.
• • Patient with contraindications to PPC or MAD therapy
• • Patient with unstable heart disease or New York Heart Association class III or IV heart failure
• • Patient unable to complete the study